Evidence map›Paper›PMID 34289398›Full record

ReviewJournal of cardiac failure2021

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.

Petter Bjornstad, Peter J Greasley, David C Wheeler, Glenn M Chertow, Anna Maria Langkilde, Hiddo J L Heerspink, DaniëL H Van Raalte

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiac failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Review
  15. Review
  16. Hypertensive Heart Failure.Journal of clinical medicine · 2023
    Review
  17. Review
  18. Diuretics in pediatrics.European journal of pediatrics · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 5 countries.

Petter BjornstadUniversity of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado.
Peter J GreasleyBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
David C WheelerDepartment of Renal Medicine, University College London, London, UK; The George Institute for Global Health, Sydney, Australia.
Glenn M ChertowDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Anna Maria LangkildeBioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Hiddo J L HeerspinkThe George Institute for Global Health, Sydney, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
DaniëL H Van RaalteDiabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, location VUMC, Amsterdam, the Netherlands. Electronic address: d.vanraalte@vumc.nl.
AstraZeneca (Sweden) · SEAmsterdam University Medical Centers · NLStanford University · USThe George Institute for Global Health · AUUniversity of Colorado Anschutz Medical Campus · USUniversity of Groningen · NL

Funding

Unraveling the Impact of Per- and Polyfluoroalkyl Substances on Early Kidney Injury in Adolescents with Obesity and DiabetesR01DK129211 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Petter Bjornstad · 2021 to 2026
$3.9M
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes StudyK23DK116720 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BJORNSTAD, PETTER · 2018 to 2022
$963k
Measuring metabolically active kidney tissue in autosomal dominant polycystic kidney diseaseR21DK129720 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BJORNSTAD, PETTER, GITOMER, BERENICE YOLANDE · 2021 to 2021
$242k
NIDDK NIH HHS K23 DK116720NIDDK NIH HHS R01 DK129211NIDDK NIH HHS R21 DK129720
6 · The paper itself

Abstract

Concomitant type 2 diabetes and chronic kidney disease increases the risk of heart failure. Recent studies demonstrate beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on chronic kidney disease progression and heart failure hospitalization in patients with and without diabetes. In addition to inhibiting glucose reabsorption, SGLT2 inhibitors decrease proximal tubular sodium reabsorption, possibly leading to transient natriuresis. We review the hypothesis that SGLT2 inhibitor's natriuretic and osmotic diuretic effects mediate their cardioprotective effects. The degree to which these benefits are related to changes in sodium, independent of the kidney, is currently unknown. Aside from effects on osmotically active sodium, we explore the intriguing possibility that SGLT2 inhibitors could also modulate nonosmotic sodium storage. This alternative hypothesis is based on emerging literature that challenges the traditional 2-compartment model of sodium balance to provide support for a 3-compartment model that includes the binding of sodium to glycosaminoglycans, such as those in muscles and skin. This recent research on nonosmotic sodium storage, as well as direct cardiac effects of SGLT2 inhibitors, provides possibilities for other ways in which SGLT2 inhibitors might mitigate heart failure risk. Overall, we review the effects of SGLT2 inhibitors on sodium balance and sensitivity, cardiac tissue, interstitial fluid and plasma volume, and nonosmotic sodium storage.

Indexed as

Diabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsGlucoseHumansSodiumGlucoseSodiumSodium-Glucose Transporter 2 InhibitorsHeart failurenatriuresisnonosmotic sodiumSGLT2 inhibitors

Identifiers

PMID34289398
PMCPMC8759453
OpenAlexW3183644076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.